Tianlei Xie
Nanjing, 210008, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Entinostat overcomes cisplatin resistance in bladder cancer by promoting H3K18la-mediated DHRS2 expression and nuclear translocation to suppress the AKR1C3-androgen axis.
Journal: Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy
Published: October 11, 2025
HDAC2 as a therapeutic target in bladder cancer: insights into the altered epigenetic regulation and lysine lactylation.
Journal: Journal of experimental & clinical cancer research : CR
Published: July 03, 2025
Multi-cohort validation of Ascore: an anoikis-based prognostic signature for predicting disease progression and immunotherapy response in bladder cancer.
Journal: Molecular cancer
Published: October 05, 2023
Membrane-associated RING-CH 7 inhibits stem-like capacities of bladder cancer cells by interacting with nucleotide-binding oligomerization domain containing 1.
Journal: Cell & bioscience
Published: July 25, 2023
Second generation androgen receptor antagonist, TQB3720 abrogates prostate cancer growth via AR/GPX4 axis activated ferroptosis.
Journal: Frontiers in pharmacology
Published: November 28, 2022
Showing 1-8 of 8
Last Updated: 09/26/2026